MINI FUTURE LONG - ZEALAND PHARMA | Market Closed - Börse Stuttgart 08:12:34 28/05/2024 BST | ||
| 1.66 EUR | +8.50% |
|
| Current month | -9.78% | ||
| 1 month | -5.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 1.66 | +8.50% |
| 27/05/24 | 1.53 | +26.45% |
| 24/05/24 | 1.21 | -15.38% |
| 23/05/24 | 1.43 | -5.30% |
| 22/05/24 | 1.51 | -0.66% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 08:12 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG1PNX |
| ISIN | DE000MG1PNX8 |
| Date issued | 04/04/2024 |
| Strike | 493.2 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.4 € |
|---|---|
| Lowest since issue | 1.18 € |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
614.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+27.84%
- Stock Market
- Certificates
- Certificat
